Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Michael A. Kroll"'
Autor:
Caleb J. Kroll, Michael H. Kroll
Publikováno v:
Journal of Thrombosis and Haemostasis. 21:18-20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8110fc07f72fcf7722477a9f111d04a
https://doi.org/10.1016/j.jtha.2022.11.003
https://doi.org/10.1016/j.jtha.2022.11.003
Autor:
Ang Li, Giordana De Las Pozas, Clark R. Andersen, Chijioke C. Nze, Katy M. Toale, Emily M. Milner, Nathanael R. Fillmore, Elizabeth Yu Chiao, Cristhiam Rojas Hernandez, Michael H. Kroll, Kelly W. Merriman, Christopher R. Flowers
Publikováno v:
American Journal of Hematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ebd34fc1df607c97fda9d99cc4ac8a9
https://doi.org/10.1002/ajh.26928
https://doi.org/10.1002/ajh.26928
Autor:
Carme Font, Juan Esteban Gomez-Mesa, Juan Jose López-Núñez, Caterina Calderón, Stephania Galindo-Coral, Carol C. Wu, Junsheng Ma, Michael H. Kroll, Cristhiam Mauricio Rojas-Hernandez
Purpose Therapy for cancer associated-venous thromboembolism (VTE) includes long term anticoagulation, which may have substantial impact on the health-related quality of life (HRQL) of patients. We assessed patient-reported outcomes to characterize t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a2fd9a862950718378cfdcd42a8be87
https://doi.org/10.21203/rs.3.rs-1693582/v1
https://doi.org/10.21203/rs.3.rs-1693582/v1
Autor:
Ahmed Elakkad, Steven Y. Huang, Sanjay Gupta, Bruno C. Odisio, Ashley Hill, Alda L. Tam, J. Kuban, Ethan Miller, Michael H. Kroll, Michael J. Overman, Armeen Mahvash, Sharjeel H. Sabir, Rahul A. Sheth
Publikováno v:
Abdominal Radiology. 45:2886-2894
Partial splenic artery embolization (PSAE) has shown promise in increasing platelet counts in cancer patients with hypersplenism-related thrombocytopenia. The purpose of this study was to identify response predictors and to longitudinally evaluate PS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::702c93fb4f566d8ff1a6de9d317494f1
https://doi.org/10.1007/s00261-020-02523-5
https://doi.org/10.1007/s00261-020-02523-5
Autor:
Michael H. Kroll
Publikováno v:
Approach to Internal Medicine ISBN: 9783030729790
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fade4a0e91075bdbf06936b4e9a393f
https://doi.org/10.1007/978-3-030-72980-6_6
https://doi.org/10.1007/978-3-030-72980-6_6
Publikováno v:
Blood. 139(25)
Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food and Drug Administration for the treatment of 14 solid tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f9c1bd91d16890f7888c057562fd3ab
https://pubmed.ncbi.nlm.nih.gov/34610113
https://pubmed.ncbi.nlm.nih.gov/34610113
Autor:
Shuju Feng, Xiaowen Liang, Miguel A Cruz, Hangoc Vu, Zhou Zhou, Naresh Pemmaraju, Jing-Fei Dong, Michael H Kroll, Vahid Afshar-Kharghan
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e73715 (2013)
Complement factor H (fH) is a plasma protein that regulates activation of the alternative pathway, and mutations in fH are associated with a rare form of thrombotic microangiopathy (TMA), known as atypical hemolytic uremic syndrome (aHUS). A more com
Externí odkaz:
https://doaj.org/article/45d0d74a491a40a38598b930247fe0f1
Autor:
Teodora Donisan, Peter Kim, Cezar Iliescu, Saamir Hassan, Thein Hlaing Oo, Konstantinos Charitakis, Cheryl F Hirsch-Ginsberg, Jean-Bernard Durand, Dinu Valentin Balanescu, Konstantinos Marmagkiolis, Juan Lopez-Mattei, Nicolas Palaskas, Mehmet Cilingiroglu, Ali M. Agha, Michael H. Kroll, Clarence Gill
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 7 (2020)
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine
Objectives: To evaluate the role of platelet count and thromboelastogram (TEG) in the treatment of thrombocytopenic cancer patients with suspected coronary artery disease (CAD).Background: Cancer patients with CAD and thrombocytopenia are often treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb248c059119cc5c10fac8cca815fee
https://www.frontiersin.org/article/10.3389/fcvm.2020.00009/full
https://www.frontiersin.org/article/10.3389/fcvm.2020.00009/full
Autor:
Lisa S. Chen, Varsha Gandhi, Wei Qiao, William G. Wierda, Qi Wu, Prithviraj Bose, Xuelin Huang, Nichole Cruz, Yongying Jiang, Nitin Jain, Philip A. Thompson, Michael J. Keating, Michael H. Kroll, Shuju Feng
Publikováno v:
Blood. 132:2249-2259
Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic leukemia (CLL). We previously demonstrated a decline in Bruton’s tyrosine kinase (BTK) protein levels in CLL cells after 1 cycle of ibrutinib, suggesting ibru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8542190bf1e55673b2841862b7aac9f
https://doi.org/10.1182/blood-2018-06-860593
https://doi.org/10.1182/blood-2018-06-860593
Autor:
Courtney D. DiNardo, Kamal Chamoun, Naveen Pemmaraju, Marisa J Hornbaker, Tapan M. Kadia, Madeleine Nguyen-Cao, Sanam Loghavi, Marina Konopleva, Jeffrey L. Jorgensen, Michael Andreeff, Shimin Hu, Michael H. Kroll, Christopher B. Benton
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-5 (2018)
Experimental Hematology & Oncology
Experimental Hematology & Oncology
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56. Historically, patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660a19f19b2c5cd25b7ab2e4ae440605
http://link.springer.com/article/10.1186/s40164-018-0117-6
http://link.springer.com/article/10.1186/s40164-018-0117-6